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Objective: To determine the prevalence of vertebral fractures (VFs) after 5 years of disease activity score
(DAS)-steered treatment in patients with early rheumatoid arthritis (RA) and to investigate the association of VFs
with disease activity, functional ability and bone mineral density (BMD) over time.
Methods: Five-year radiographs of the spine of 275 patients in the BeSt study, a randomized trial comparing four
treatment strategies, were used. Treatment was DAS-steered (DAS≤ 2.4). A height reduction >20% in one vertebra
was defined a vertebral fracture. With linear mixed models, DAS and Health Assessment Questionnaire (HAQ) scores
over 5 years were compared for patients with and without VFs. With generalized estimating equations the
association between BMD and VFs was determined.
Results: VFs were observed in 41/275 patients (15%). No difference in prevalence was found when stratified for
gender, prednisone use and menopausal status. Disease activity over time was higher in patients with VFs, mean
difference 0.20 (95% CI: 0.05-0.36), and also HAQ scores were higher, independent of disease activity, with a mean
difference of 0.12 (95% CI: 0.02-0.2). Age was associated with VFs (OR 1.06, 95% CI: 1.02-1.09), mean BMD in spine
and hip over time were not (OR 95% CI, 0.99: 0.78-1.25 and 0.94: 0.65-1.36, respectively).
Conclusion: After 5 years of DAS-steered treatment, 15% of these RA patients had VFs. Higher age was associated
with the presence of VFs, mean BMD in hip and spine were not. Patients with VFs have greater functional disability
over time and a higher disease activity, suggesting that VFs may be prevented by optimal disease activity
suppression.
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Treatment strategyBackground
Vertebral fractures are more common in patients with
RA compared to the general population [1-5]. Patients
with fractures have a decreased functional ability and a
higher mortality compared to patients without fractures
[3,6-9]. In patients with RA, in addition to established
risk factors such as lower body mass index (BMI),
increased age, lower bone mineral density (BMD) and* Correspondence: l.dirven@lumc.nl
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reproduction in any medium, provided the orthe use of corticosteroids, longer disease duration and
more severe disease are associated with osteoporosis and
vertebral fractures [1-5,7,10]. It is suggested that an ap-
propriate control of disease may be protective of the
quality and density of bone and thus prevent the devel-
opment of vertebral fractures [11]. Such control of dis-
ease is generally more effectively achieved with disease
activity score (DAS) steered treatment strategies [12,13]
and more early with initial combination therapy with a syn-
thetic disease-modifying antirheumatic drugs (DMARDs)
and prednisone or anti tumor necrosis factor (anti-TNF)
[14-17].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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less vertebral fractures, we conducted a cross-sectional
analysis to determine the prevalence of vertebral frac-
tures after 5 years of DAS-steered treatment in patients
with early active RA, treated according to four different
treatment strategies. In addition, we investigated the as-
sociation of vertebral fractures with disease activity,
functional ability and mean bone mineral density over
time.Methods
Patients
All measurements were performed in the setting of the
BeSt study, a randomized clinical trial (Netherlands trial
register, NTR265) comparing four different treatment
strategies in DMARD-naïve patients who fulfilled the
revised 1987 American College of Rheumatology (ACR)
inclusion criteria for RA. The ethics committees of all
participating centers approved the study protocol and
patients gave their written informed consent.
Patients were treated according to a dynamic protocol
starting with (1) sequential monotherapy, (2) step-up ther-
apy, (3) initial combination therapy with tapered high-dose
prednisone or (4) initial combination therapy including
infliximab. Treatment adjustments were made using the
disease activity score (DAS) every three months and treat-
ment aimed at a DAS ≤2.4. All data was collected pro-
spectively and more details on the BeSt study design were
previously published [16,18].Assessment of vertebral fractures
Radiographs of the lateral thoracic and lumbar spine,
taken after 5 years of follow-up, were available in 275 of
the 508 patients. 434/508 patients were still under
follow-up after 5 years of treatment and in 159/434
patients radiographs were not made, mostly due to logis-
tic reasons in the various hospitals. This includes study
personnel failing to send patients for radiographs and
radiology personnel failing to make the radiographs as
requested by protocol, but also some patients refused.
Vertebral fractures were assessed with direct measure-
ment and in consensus by two experienced readers (LD,
WFL) using the Genant method. Deformities were clas-
sified as a wedge deformity, biconcave deformity or
crush deformity. To quantify the severity of the frac-
tures, the reduction in anterior, middle and/or posterior
vertebral heights were measured and indicated as grade
1-3 deformities. Grade 1 represents a reduction in verte-
bral heights of 20-25%, grade 2 a reduction of 25-40%
and grade 3 a reduction of more than 40%. Patients with
a reduction of at least 20% (grade 1) in at least one ver-
tebra were defined as fractured.BMD measurements
BMD measurements of the lumbar spine in antero-
posterior view and/or the left total hip at baseline and
yearly up to year 5 were available in 194 patients. Dual
energy X-ray absorptiometry (DEXA) was available in
eight participating centers, four of which used a Hologic
QDR 4500 (Hologic, Waltham, MA, USA) and four used
a Lunar DPX (Lunar, Madison, WI, USA). The mean
BMD is calculated for each individual patient from mea-
surements performed using the same device.
Statistical analysis
Demographic and clinical baseline characteristics for
patients with and without vertebral fractures were com-
pared. Differences were tested using the chi-square test
for categorical data and either the students T-test or
Mann Whitney U test for continuous data, depending
on the distribution of the tested variable.
Prevalence of vertebral fractures after 5 years of treat-
ment was determined in the whole patient group as well
as stratified for gender, menopausal status, use of corti-
costeroids and bisphosphonates and treatment strategy.
Using linear mixed models (LMM) with a Toeplitz co-
variance structure, DAS and HAQ scores (continuous out-
come variables) over 5 years were compared for patients
with and without vertebral fractures. In the model with
DAS as outcome, estimates were adjusted for gender and
baseline age, DAS and BMI. In the model with HAQ score
as outcome, estimates were adjusted for baseline age,
HAQ, BMI, gender and the DAS score over 5 years. Using
generalized estimating equations (GEE) with an exchange-
able covariance structure, the association between the
presence of vertebral fractures (dichotomous outcome)
and BMD was assessed. The association between the
prevalence of vertebral fractures and BMD of the spine
and the total hip were first analyzed univariately (crude
OR) and next they were analyzed adjusted for year, age,
BMI, postmenopausal status, use of bisphosphonates, vita-
min D and/or calcium, HRT and the use of prednisone
(adjusted OR).
With univariate regression analyses we tested baseline
variables (age, gender, symptom duration, DAS, HAQ,
BMI, erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), RF, ACPA, BMD of the spine and BMD
of the hip, smoking status and treatment strategy) for as-
sociation with vertebral fractures after 5 years. Variables
showing an association (p < 0.10) with vertebral fractures
were entered as possible predictors in a multivariate lo-
gistic regression and significant independent predictors
were identified with a backward selection procedure,
using a p-value of 0.10 as the removal criterion. All tests
were two-tailed and p < 0.05 was considered to be statis-
tically significant. To analyze the data, SPSS version 17.0
software (SPSS, Chicago, IL, USA) was used.
Figure 1 Number of vertebral fractures of the thoracic and
lumbar vertebrae according the Genant method; Grade 1
represents a reduction in vertebral heights of 20-25%, grade 2 a
reduction of 25-40% and grade 3 a reduction of more than 40%.
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Patients included in this study were on average 54 years
old at baseline and most were female (67%), of whom
18% were postmenopausal. Rheumatoid arthritis at base-
line was active with a mean DAS of 4.4 and a mean
HAQ score of 1.3. Sixty-six and 63% of the patients were
RF and ACPA positive, respectively (table 1).
There were no significant differences in baseline char-
acteristics (disease activity, age, BMI, gender, smoking
and RF and ACPA status, symptom duration, ESR and
CRP) between the 275 patients with radiographs of the
spine and the patients without (data not shown), with
the exception of baseline HAQ, which was lower in patients
with radiographs of the spine (1.3 versus 1.5). Patients with
BMD measurements had similar baseline characteristics as
patients without, with the exception of BMI (25.5 versus
26.3 kg/m2) and HAQ score (1.3 versus 1.5).
Prevalence of vertebral fractures
Vertebral fractures were observed in 41/275 patients
(15%). Of the patients with fractures, 73% had one verte-
bral fracture, 22% had two vertebral fractures, 2.5% had
three and 2.5% four vertebral fractures. In total, 55 of
the 3691 vertebrae (1.5%) were fractured and most of
these fractures were thoracic (85%). Most fractures were
a grade 1 reduction (69%), 27% had a grade 2 reduction
and 4% a grade 3 reduction (Figure 1).
Next, the prevalence of vertebral fractures was deter-
mined after stratifying for known risk factors. Patients
with vertebral fractures after 5 years were older thanTable 1 Baseline characteristics of the 275 out of 508 patient
after 5 years of treatment
Baseline characteristics Without vertebral fractur
Age, mean± SD years 53 (13)
Female gender, no. (%) 159 (68)
Symptom duration, median (IQR) weeks 24 (14-50)
DAS, mean± SD 4.4 (0.9)
HAQ, mean± SD 1.3 (0.6)
BMI, mean± SD 26 (4)
ESR, mean± SD 36 (19-56)
CRP, mean± SD 20 (9-52)
RF positive, no. (%) 152 (65)
ACPA positive, no. (%) 148 (64)
Smoking yes, no (%) 80 (34)
Treatment strategy, no. (%)
Sequential monotherapy 67 (28.6)
Step-up therapy 48 (20.5)
Initial combo with prednisone 55 (23.5)
Initial combo with infliximab 64 (27.4)
IQR, inter quartile range; DAS, disease activity score; HAQ, Health assessment Quest
sedimentation rate; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide anpatients without vertebral fractures (60 versus 53 years,
p < 0.05) and were more often smokers (51% versus 34%,
p < 0.05). The prevalence of vertebral fractures was simi-
lar in men and women (17% versus 14%, p= 0.568) and
similar in pre- and postmenopausal women (9% versus
16%, p= 0.278). No difference in prevalence of vertebral
fractures was found for the four different treatment
groups (12, 17, 15 and 16% for group 1-4, respectively,
p= 0.833). We found a prevalence of vertebral fractures
of 19% in patients who ever used prednisone during
5 years of treatment and of 13% in those who had never
used prednisone (p= 0.177). Similar results were found
when patients were stratified for prednisone use mores in the BeSt study with and without vertebral fractures
es (n = 234) With vertebral fractures (n = 41) p-value
60 (11) 0.001
26 (63) 0.568
23 (15-49) 0.673
4.2 (0.7) 0.069
1.4 (0.7) 0.594
25 (4) 0.545
44 (26-57) 0.098
30 (12-51) 0.298
29 (71) 0.472
24 (59) 0.543
21 (51) 0.037
0.833
9 (22)
10 (24.4)
10 (24.4)
12 (29.3)
ionnaire; BMI, body mass index ; CRP, C-reactive protein; ESR, erythrocyte
tibodies.
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and when stratified for non-vertebral fractures (data not
shown). Finally, use of bisphosphonates in 5 years time
was similar in patients with or without vertebral frac-
tures (25% versus 29%, p= 0.523) and similar results
were found for use of calcium, vitamin D and hormone
replacement therapy (data not shown).Vertebral fractures and BMD
Results of a Linear Mixed Models analysis show that the
mean predicted BMD values of the spine were slightly
lower over time in patients with vertebral fractures (1.03
versus 1.06 g/cm2, p= 0.283), while remaining stable
over 5 years of treatment in both groups (Figure 2A).
Mean predicted BMD values of the total hip were also
slightly lower for patients with vertebral fractures (0.89
versus 0.93 g/cm2, p= 0.233), and decreased over time in
patients with or without vertebral fractures (Figure 2B).Figure 2 Bone mineral density (BMD) of the spine (figure A) and the
without vertebral fractures.Mean BMD over time in the spine and mean BMD
over time in the total hip were not significantly asso-
ciated with the presence of vertebral fractures after five
years of DAS-steered treatment (OR 0.86, 95% CI: 0.68-
1.09 and OR 0.77, 95% CI: 0.54-1.11, respectively), also
after adjustment for possible confounders (spine, OR
0.99, 95% CI: 0.78-1.25; hip, OR 0.94, 95% CI: 0.65-1.36).
In the multivariate GEE models, only age was independ-
ently associated with the presence of vertebral fractures
after 5 years of treatment with an OR (95% CI) of 1.04
(1.02-1.09) in the spine and an OR (95% CI) of 1.05
(1.01-1.10) in the hip.Predictors of vertebral fractures
In the univariate regression analysis and subsequently in
the multivariate logistic regression analysis, baseline age
and baseline smoking status were associated (p < 0.10)
with having a vertebral fracture after 5 years of DAS-total hip left (figure B) over 5 years time for patients with and
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smoking OR 2.5, 95% CI: 1.2-5.0).
Vertebral fractures and the association with disease
activity and functional ability
In patients with vertebral fractures there was a trend for
a lower baseline DAS (p= 0.069), but over 5 years time
patients with vertebral fractures had a higher DAS over
time compared to patients without vertebral fractures,
with a mean difference of 0.20 (95% CI: 0.05-0.36)
(Figure 3A). In addition, functional ability over time was
worse in patients with vertebral fractures than in
patients without vertebral fractures (unadjusted mean
difference 0.15 (95% CI: 0.01-0.29) which was independ-
ent of disease activity over the same period (adjusted
mean difference 0.12 (95% CI: 0.02-0.2) (Figure 3B).
Discussion
In this longitudinal cohort of patients with early active
RA we conducted a cross-sectional analysis and found a
prevalence of vertebral fractures of 15% after 5 years of
DAS-steered treatment. The majority of these patientsFigure 3 Disease activity scores (figure A) and HAQ scores (predicted
concurrent DAS) (figure B) over 5 years time for patients with and wi(73%) had only one vertebral fracture and most deform-
ities were grade 1 (69%).
The prevalence is lower than previously reported in
non-DAS steered cohorts (19-36%) [1-3,7,10,19]. This
suggests that adequate control of disease activity in earl-
ier RA, with a treat-to-target approach, may protect
against the occurrence of vertebral fractures. However,
the prevalence of vertebral fractures in the general popu-
lation is about 5% [2,10], which suggests that vertebral
fractures may be a symptom of RA even if the disease
activity appears relatively well controlled.
Most previous studies have focused on the prevalence
of vertebral fractures in female RA patients, and postme-
nopausal women appeared to be especially at risk [6]. In
a population-based cohort study of men and women
older than 55 years, the incidence of vertebral fractures
was higher in women than in men with a decrease in
BMD as an independent predictor [20]. We found that
the prevalence of vertebral fractures in male patients in
our cohort was not statistically different from the preva-
lence in female patients (17% versus 14%, respectively).
The prevalence of vertebral fractures in males wasscores based on a Linear Mixed Models analysis, corrected for
thout vertebral fractures.
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higher than in premenopausal females (9%). This is
probably related to the fact that males were of similar
age as the postmenopausal females (57 versus 58 years,
p= 0.281). We found higher age to be independently
associated with a high prevalence of vertebral fractures.
Also smoking was a risk factor for vertebral fractures.
In contrast to other studies, we found no association
with the use of prednisone [3,6,10]. No difference was
found in vertebral fractures between the four treatment
groups, where in group 3 patients were initially treated
with a high dose of prednisone (60 mg daily, tapered in
7 weeks to 7.5 mg daily). Ever use of prednisone was not
associated with more vertebral fractures compared to
never use, nor was use of prednisone longer than a year
compared with use of prednisone less than a year. This
suggests that the beneficial effects of prednisone on sup-
pression of disease activity outweigh the potentially dele-
terious effects on bone quality and vertebral fractures
[11,21].
In this cohort, use of bisphosphonates appeared not to
be associated with a lower prevalence of vertebral frac-
tures. This is at odds with previous reports that the use
of bisphosphonates reduces the risk of vertebral and
non-vertebral fractures [21-23]. In daily clinical practice,
bisphosphonates are only prescribed if risk factors for
bone mineral density loss are present, implying con-
founding by indication. In addition, bisphosphonates
could have been started after a fracture has occurred,
which also might explain why we found no protective ef-
fect. Most important independent risk factor of vertebral
fractures after 5 years was a higher age.
It has been demonstrated that lower BMD is asso-
ciated with the presence of vertebral fractures.[3,10] We
previously reported that BMD loss in the BeSt study was
not depending on prednisone use but on suppression of
disease activity [22]. Since also rheumatic disease activity
over time was slightly higher in patients with vertebral
fractures compared to patients without vertebral frac-
tures (mean difference 0.19), these findings support the
hypothesis that there is a relation between disease activ-
ity and poor vertebral bone quality. We did not find a
statistically significant association between BMD and
vertebral fractures, although mean BMDs over time of
the spine and hip of patients with vertebral fractures
were somewhat lower than patients without vertebral
fractures. Probably, this is related to the small changes
in BMD over time, as a result of adequate disease con-
trol. In addition, after adjustment for age, itself signifi-
cantly associated with a higher prevalence of vertebral
fractures, the association between BMD and vertebral
fractures becomes smaller. It thus appears that age
related factors play an important role in the develop-
ment of vertebral fractures.More of clinical importance, functional disability over
time was higher in patients with vertebral fractures com-
pared to those without. This association was earlier
described in a cross-sectional study, which sheds no
light on the possible mechanism behind it [24]. We
found that the higher functional disability in patients
with vertebral fractures was independent of disease ac-
tivity and age, suggesting that patients with vertebral
fractures suffer functional impairment due to the verte-
bral fractures or the underlying bone condition, inde-
pendent of rheumatic symptoms. It may also be possible
that HAQ deterioration occurred before the vertebral
fractures, but as HAQ deterioration is dependent on dis-
ease activity in the early phases of RA [25] and as we
found that patients with vertebral fractures have higher
HAQ over time irrespective of DAS over time, it seems un-
likely that HAQ had preceded vertebral fractures, as earlier
proposed [24]. Therefore, prevention of vertebral fractures
is important in terms of reducing functional disability.
A limitation of this study is the absence of baseline
radiographs of the spine. We are therefore not sure
when the vertebral fracture occurred in relation to the
onset of RA and the start of antirheumatic and anti-
resorptive treatment. It is possible that fractures oc-
curred before RA was diagnosed, in which case the
prevalence of vertebral fractures in well suppressed RA
is even less than we observed, or that bisphosphonates
were started after a fracture has occurred. Although the
prevalence of vertebral fractures was determined cross-
sectionally, the differences in disease activity over time
between patients with and without vertebral fractures do
suggest that inflammation plays a role in the occurrence
of vertebral fractures.
In conclusion, in a cohort of patients with recent-onset
active RA, after 5 years of DAS-steered treatment the
prevalence of vertebral fractures was with 15% higher
than in the healthy population and similar for males and
females. Independent predictors for vertebral fractures
were age and smoking. Mean BMD over time of the
spine and hip were not associated with the presence of
vertebral fractures and vertebral fractures did not occur
more in patients who used prednisone than in patients
who did not. Patients with vertebral fractures suffer
greater functional disability over time than patients with-
out, independent of a slightly higher rheumatic disease
activity. This indicates that vertebral fractures can be seen
as bony damage of rheumatoid inflammation and may be
prevented by optimal disease activity suppression.
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